Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Anecatibin Fumarate in Hepatic Impairment vs Normal Liver Function
NCT07538973Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of unecritinib in lung cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration at 5 days, Area Under the Curve from time zero to time of last quantifiable concentration at 5 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
unecritinib
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07538973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538973.